Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.36 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.36 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.36 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.36 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.36 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 4/20 | 0.34 |
| ▸ | ACHE | P22303 | 2/20 | 0.33 |
| ▸ | CASP2 | P42575 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL181009 | 0.97 | SMN1; SMN2 (0.41) | SMN1; SMN2HPGDHTTALDH1A1HDAC3 | |
| SCHEMBL1255461 | 0.97 | SMN1; SMN2 (0.41) | SMN1; SMN2HPGDHTTALDH1A1HDAC3 | |
| SCHEMBL2734922 | 0.96 | SMN1; SMN2 (0.39) | SMN1; SMN2HPGDHTTALDH1A1HDAC3 | |
| SCHEMBL17767812 | 0.93 | SMN1; SMN2 (0.50) | SMN1; SMN2HPGDHTTALDH1A1HDAC3 | |
| SCHEMBL26382038 | 0.93 | SMN1; SMN2 (0.50) | SMN1; SMN2HPGDHTTALDH1A1HDAC3 | |
| SCHEMBL20999873 | 0.93 | SMN1; SMN2 (0.50) | SMN1; SMN2HPGDHTTALDH1A1HDAC3 | |
| SCHEMBL17767809 | 0.93 | SMN1; SMN2 (0.50) | SMN1; SMN2HPGDHTTALDH1A1HDAC3 | |
| SCHEMBL17168743 | 0.93 | SMN1; SMN2 (0.50) | SMN1; SMN2HPGDHTTALDH1A1HDAC3 | |
| SCHEMBL21117960 | 0.92 | SMN1; SMN2 (0.49) | SMN1; SMN2HPGDHTTALDH1A1HDAC3 | |
| SCHEMBL8663263 | 0.92 | SMN1; SMN2 (0.37) | SMN1; SMN2HPGDHTTTSHRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 220 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250352663-A1 | Nanoclusters Functionalized with Adenosine Triphosphate or an Analogue and Their Use | UNIV LELAND STANFORD JUNIOR (US) | 2025-11-20 | — | — | US | disclosed |
| US-11998615-B2 | Functionalized nanoparticles and their use in treating bacterial infections | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-06-04 | — | — | US | disclosed |
| US-20240148882-A1 | METHODS OF TREATING AN OCULAR DISEASE OR DISORDER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-05-09 | — | — | US | disclosed |
| WO-2024044636-A2 | NANOCLUSTERS FUNCTIONALIZED WITH ADENOSINE TRIPHOSPHATE OR AN ANALOGUE AND THEIR USE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2023164224-A1 | FUNCTIONALIZED NANOCLUSTERS AND THEIR USE IN TREATING BACTERIAL INFECTIONS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-08-31 | — | — | WO | disclosed |
| US-11723982-B2 | Methods of treating an ocular disease or disorder | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-15 | — | — | US | disclosed |
| US-20230149561-A1 | Functionalized Nanoparticles and Their Use in Treating Bacterial Infections | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2023-05-18 | — | — | US | disclosed |
| US-20220339293-A1 | FUNCTIONALIZED NANOPARTICLES AND THEIR USE IN TREATING BACTERIAL INFECTIONS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2022-10-27 | — | — | US | disclosed |
| US-20220265763-A1 | POLYPEPTIDE-POLYMER CONJUGATES AND METHODS OF USE THEREOF | UNIV CALIFORNIA (US) | 2022-08-25 | — | — | US | disclosed |
| US-20220227855-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF ANGIOGENESIS RELATED DISEASES | THE UNIVERSITY OF MASSACHUSETTS | 2022-07-21 | — | — | US | disclosed |
| US-20040115168-A1 | Interferon beta: remodeling and glycoconjugation of interferon beta | NEOSE TECHNOLOGIES, INC. | 2004-06-17 | — | — | US | disclosed |
| US-20040082026-A1 | Interferon alpha: remodeling and glycoconjugation of interferon alpha | NEOSE TECHNOLOGIES, INC. | 2004-04-29 | — | — | US | disclosed |
| US-20040077836-A1 | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF | NEOSE TECHNOLOGIES, INC. | 2004-04-22 | — | — | US | disclosed |
| WO-2004033651-A2 | ERYTHROPOIETIN: REMODELING AND GLYCOCONJUGATION OF ERYTHROPOIETIN | NEOSE TECHNOLOGIES, INC. (US) | 2004-04-22 | — | — | WO | disclosed |
| US-20040063911-A1 | Protein remodeling methods and proteins/peptides produced by the methods | NEOSE TECHNOLOGIES, INC. | 2004-04-01 | — | — | US | disclosed |
| US-20040043446-A1 | Alpha galalctosidase a: remodeling and glycoconjugation of alpha galactosidase A | NEOSE TECHNOLOGIES, INC. | 2004-03-04 | — | — | US | disclosed |
| US-20040001892-A1 | Tunable, semi-interpenetrating polymer networks (sIPNS) for medicine and biotechnology | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-01-01 | — | — | US | disclosed |
| WO-2003031464-A2 | REMODELING AND GLYCOCONJUGATION OF PEPTIDES | NEOSE TECHNOLOGIES, INC. (US) | 2003-04-17 | — | — | WO | disclosed |
| EP-1218413-A2 | ENGINEERING ANTIBODIES THAT BIND IRREVERSIBLY | The Regents of the University of California (US) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001022922-A2 | ENGINEERING ANTIBODIES THAT BIND IRREVERSIBLY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077836-A1 | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF | CSF3R, CSF1R, GMFG | SMN1; SMN2 4204/4885HPGD 2582/4885HTT 3557/4885 |
| US-20040082026-A1 | Interferon alpha: remodeling and glycoconjugation of interferon alpha | IFNG, IFNAR1, IRF3 | SMN1; SMN2 4636/4885HPGD 2358/4885HTT 4331/4885 |
| US-20040063911-A1 | Protein remodeling methods and proteins/peptides produced by the methods | PTMS, ANPEP, SMURF1 | SMN1; SMN2 4161/4885HPGD 4080/4885HTT 1745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.